UNICHEM LABORATORIES LTD.
NSE : UNICHEMLABBSE : 506690ISIN
CODE : INE351A01035Industry : Pharmaceuticals & DrugsHouse
: Private
BSE559.50-0.7 (-0.12 % )
PREV CLOSE (Rs.) 560.20
OPEN PRICE (Rs.) 555.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3287
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE560.05 1.7 (+0.3 % )
PREV CLOSE(Rs.) 558.35
OPEN PRICE (Rs.) 555.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 20860
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Financial ratio
| Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -28.72 | 4.70 | 4.88 | -8.55 | -3.38 |
| CEPS(Rs) | -12.61 | 17.64 | 16.86 | 3.05 | 5.94 |
| DPS(Rs) | 0.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 344.18 | 370.39 | 362.05 | 358.85 | 371.69 |
| Tax Rate(%) | -14.67 | -50.49 | 33.32 | -24.83 | 57.34 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -3.39 | 5.73 | 7.38 | -4.60 | -7.08 |
| EBIT Margin(%) | -11.84 | 2.21 | 4.58 | -3.66 | -4.44 |
| Pre Tax Margin(%) | -13.13 | 1.73 | 4.17 | -4.37 | -5.08 |
| PAT Margin (%) | -15.06 | 2.60 | 2.78 | -5.45 | -2.17 |
| Cash Profit Margin (%) | -6.61 | 9.78 | 9.61 | 1.95 | 3.54 |
| Performance Ratios | |||||
| ROA(%) | -6.22 | 1.03 | 1.10 | -1.92 | -0.81 |
| ROE(%) | -8.04 | 1.28 | 1.35 | -2.34 | -0.97 |
| ROCE(%) | -5.60 | 1.00 | 2.11 | -1.46 | -1.85 |
| Asset Turnover(x) | 0.41 | 0.40 | 0.40 | 0.35 | 0.37 |
| Sales/Fixed Asset(x) | 0.86 | 0.99 | 1.08 | 1.06 | 1.42 |
| Working Capital/Sales(x) | 1.42 | 1.16 | 1.42 | 0.99 | 0.77 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.17 | 1.01 | 0.93 | 0.94 | 0.71 |
| Receivable days | 147.31 | 107.17 | 94.63 | 136.61 | 110.26 |
| Inventory Days | 166.52 | 163.63 | 138.14 | 121.57 | 94.58 |
| Payable days | 179.25 | 201.09 | 278.03 | 278.88 | 224.32 |
| Valuation Parameters | |||||
| PER(x) | 0.00 | 55.44 | 63.44 | 0.00 | 0.00 |
| PCE(x) | -22.92 | 14.76 | 18.35 | 49.59 | 32.76 |
| Price/Book(x) | 0.84 | 0.70 | 0.85 | 0.42 | 0.52 |
| Yield(%) | 0.00 | 1.54 | 1.29 | 2.64 | 2.06 |
| EV/Net Sales(x) | 1.60 | 1.61 | 1.78 | 0.92 | 1.16 |
| EV/Core EBITDA(x) | -304.97 | 17.03 | 15.54 | 25.09 | 91.72 |
| EV/EBIT(x) | -13.50 | 73.00 | 38.80 | -25.17 | -26.12 |
| EV/CE(x) | 0.67 | 0.62 | 0.83 | 0.32 | 0.44 |
| M Cap / Sales | 1.52 | 1.44 | 1.76 | 0.97 | 1.16 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.76 | 2.81 | 11.91 | -6.47 | -14.48 |
| Core EBITDA Growth(%) | -105.85 | -14.86 | 248.94 | 171.43 | -99.55 |
| EBIT Growth(%) | -666.54 | -50.70 | 240.22 | 22.95 | -101.61 |
| PAT Growth(%) | -711.67 | -4.63 | 157.03 | -135.48 | -101.00 |
| EPS Growth(%) | -711.66 | -3.68 | 157.03 | -152.78 | -100.93 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.13 | 0.04 | 0.07 | 0.08 |
| Current Ratio(x) | 2.48 | 2.98 | 2.72 | 2.98 | 4.05 |
| Quick Ratio(x) | 1.51 | 1.89 | 1.66 | 2.28 | 3.38 |
| Interest Cover(x) | -9.19 | 4.60 | 11.06 | -5.14 | -6.96 |
| Total Debt/Mcap(x) | 0.15 | 0.18 | 0.05 | 0.17 | 0.15 |
